Replies to post #321597 on Avid Bioservices Inc (CDMO)

[war0001]

PPHM always the bridesmaid, never the bride.

I do wish that 2018 brings about some positive news as I've been beaten down so much with this stock.

[revenue_monster]

your dissertation didn’t answer the question

[north40000]

Your last paragraph, some additions to keep in mind:

1) PFM has an ongoing collaboration with MSKCC for several years; PPHM likewise.

2) PFM along with Vanderbilt-Ingram CC, Providence CC were authors with PPHM’s Dr. N. Kallinterris of the post-Sunrise prognostic and/or predictive biomarkers poster presented at AACR 2017 this past April. Even then, the data supported...”[planning of] Clinical trials combining bavituximab and immunotherapy agents such as checkpoint inhibitors...”[SUMMARY].

3) Drs Kallinterris, Kleen(Epiontis, now PFM’s VP of Immune Monitoring) were co-authors with others of the last biomarkers poster from Sunrise presented at SITC this past November; CJG has archived an image of that poster in stickies above.

It will be very interesting, IMO, to see and hear what our new BOD decides to do with all known clinical and biomarkers data extracted from Sunrise. Would one or more seamless clinical trials for multiple indications be in the offing, per licensing of PFM and MSKCC?

[biopharm]

Funny how Precision For Medicine advised by Bird & Bird to buy Epiontis (both were working with PS Targeting Biomarkers data) and now PFM just announced expansion of Biomarker platform with close to $300 Million infusion of funds being invested...(which I say has to do with new knowledge of PS Targeting Biomarkers that were discovered on Sunrise and other PS Targeting data

North, I have been making a list of more puzzle pieces but what was the first business Berkshire invested in with?


Chairman Ethan Leder commented, “We are delighted to have Berkshire rejoin us as they were a key investor in our previous business and added great value to the team.”

__________________

BERKSHIRE PARTNERS AND TPG GROWTH CO-LEAD $275 MILLION INVESTMENT AS THE COMPANY POSITIONS FOR THE NEXT PHASE OF GROWTH

BETHESDA, MD — December 19, 2017 — Precision Medicine Group (PMG) announced today that it has reached an agreement for a $275 million investment that positions the company for the next phase of growth. The transaction is being led by Berkshire Partners and TPG Growth and also includes significant participation from Precision’s co-founders and management team as well as original investors Oak Investment Partners and J.H. Whitney. This is Berkshire Partners’ first investment in PMG and for TPG Growth this represents a significant expansion of the investment position it established in December 2015.

“This is a significant milestone for the company,” said Mark Clein, CEO. “It recognizes both the progress achieved to date and the bright potential for our future. We are fortunate and gratified to have the support of our capital partners and colleagues.” Chairman Ethan Leder commented, “We are delighted to have Berkshire rejoin us as they were a key investor in our previous business and added great value to the team.”

“Precision has built a unique and compelling set of services that address the most important challenges facing biopharmaceutical and diagnostic companies,” said Chris Hadley, a Managing Director at Berkshire Partners. “We are thrilled to participate in the next leg of growth and expansion focused on accelerating development and demonstrating value for customers.”

Since its inception in 2012, PMG has grown to over 1,000 employees and 22 locations in the U.S., Canada and Europe. This investment will support the expansion of PMG’s global footprint and provide additional scale to accelerate the development, approval and commercial success of innovative treatments.

“We could not be more pleased with PMG’s progress since our initial investment in 2015,” said Matt Hobart, Partner at TPG Growth. “Operating at the intersection of drugs and diagnostics, PMG is in a unique position to drive innovations across the healthcare industry.”

About Precision Medicine Group
Formed in 2012, Precision Medicine Group is a specialized services company supporting next generation approaches to drug development and commercialization. Precision provides an integrated infrastructure that supports pharmaceutical and life sciences companies as they develop new products in the age of precision medicine. The company is headquartered in Bethesda, Maryland with offices throughout North America and Europe. For more information, visit https://www.precisionmedicinegrp.com


https://www.precisionmedicinegrp.com/pfm/article/precision-medicine-group-lands-major-new-investment/